| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| Company: Ludwig Institute for Cancer Research |
| Recipient: You |
|
| Stock and Other Ownership Interests |
| Company: Tizona Therapeutics, Inc. |
| Recipient: You |
| Company: ImVaq |
| Recipient: You |
| Company: Linneaus |
| Recipient: You |
| Company: Arsenal IO |
| Recipient: You |
| Company: Georgiamune, LLC |
| Recipient: You |
| Company: Apricity Therapeutics |
| Recipient: You |
| Company: Maverick Therapeutics |
| Recipient: You |
| Company: Ascentage Pharma |
| Recipient: You |
| Company: Larkspur |
| Recipient: You |
| Company: CellCarta |
| Recipient: You |
| Company: Xenimmune |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Sellas Life Sciences |
| Recipient: You |
| Company: Tizona Therapeutics, Inc. |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Ascentage Pharma |
| Recipient: You |
| Company: PsiOxus Therapeutics |
| Recipient: You |
| Company: Surface Oncology |
| Recipient: You |
| Company: Apricity Therapeutics |
| Recipient: You |
| Company: Recepta Biopharma |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Daiichi Sankyo,Inc |
| Recipient: You |
| Company: Dragonfly |
| Recipient: You |
| Company: Georgiamune |
| Recipient: You |
| Company: Maverick Therapeutics |
| Recipient: You |
| Company: Werewolf Therapeutics |
| Recipient: You |
| Company: Trishula Therapeutics |
| Recipient: You |
| Company: Idera Pharmaceuticals |
| Recipient: You |
| Company: Imvaq Therapeutics |
| Recipient: You |
| Company: Bicara Therapeutics |
| Recipient: You |
| Company: Truvax |
| Recipient: You |
| Company: CellCarta |
| Recipient: You |
| Company: Larkspur |
| Recipient: You |
| Company: BeiGene |
| Recipient: You |
| Company: Chugai Pharma |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Sephora |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. |
| Recipient: Your Institution |
| Please describe: I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. |
| Recipient: Your Institution |
| Please describe: I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. |
| Recipient: Your Institution |
| Please describe: I am co-inventor and receive royalties for a patent for immune modulating antibodies. |
| Recipient: Your Institution |
| Please describe: I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer |
| Recipient: Your Institution |
| Please describe: I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy
|
| Recipient: Your Institution |
| Please describe: ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 |
| Recipient: Your Institution |
| Please describe: Engineered Vaccinia Viruses for Cancer Immunotherapy
|
| Recipient: Your Institution |
| Please describe: RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY |
| Recipient: Your Institution |
| Please describe: WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT |
| Recipient: Your Institution |
| Please describe: Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 |
| Recipient: Your Institution |
| Please describe: Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment |
| Recipient: Your Institution |
| Please describe: CD40 BINDING MOLECULES AND USES THEREOF |
| Recipient: Your Institution |
| Please describe: CD40 binding Molecules and uses thereof |
| Recipient: Your Institution |
| Please describe: Anti-GITR antibodies and methods of use thereof |
| Recipient: Your Institution |
| Please describe: Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
| Recipient: Your Institution |
| Please describe: Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade |
| Recipient: Your Institution |
| Please describe: Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies |
| Recipient: Your Institution |
| Please describe: ANTIGEN-RECOGNIZING RECEPTORS TARGETING B7-H3 AND USES THEREOF |
| Recipient: Your Institution |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|